Compare Analog Devices, Inc. (ADI) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs ClearPoint Neuro Inc — how do they compare? Analog Devices, Inc. trades at $388.39 (market cap $187.00B), while ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M). The key difference: Analog Devices, Inc. is far larger — about 421× ClearPoint Neuro Inc's market cap, and Analog Devices, Inc. pays a 1.15% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| ADI | CLPT | |
|---|---|---|
Market Cap | $187.00B | $444.14M |
Sector | Technology | Health |
52-Week High | $445.48 | $29.60 |
52-Week Low | $225.20 | $8.66 |
Enterprise Value | $192.25B | $478.72M |
Dividend Yield | 1.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $389.93, up 3.34% over the past day, with a bullish technical signal and strong institutional support. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.09 exceeding expectations. Revenue for 2025 reached $11.02 billion, with a net income margin of 26.01%, though valuation ratios like P/E of 58.03 suggest premium pricing. A dividend of $1.10 per share is scheduled for payment on June 16, 2026.
The outlook for ADI is positive, driven by robust earnings performance and analyst optimism, with a consensus price target of $474.80 implying significant upside. Risks include high valuation multiples and sensitivity to semiconductor market cycles, but strong cash flow and institutional buy-in support a favorable investment case for growth-oriented investors.
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
